---
schema_version: "secwatch.filing_event.v1"
accession: "0001232524-24-000065"
form_type: "8-K"
ticker: "JAZZ"
cik: "0001232524"
company_name: "Jazz Pharmaceuticals plc"
filed_at: "2024-07-31T23:59:59+00:00"
generated_at: "2026-05-31T14:16:54.993101+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Jazz Q2 revenue >$1B record; key drugs up 13-22%; guides EPS higher

## Summary
- Xywav sales +13%, Epidiolex +22%, Rylaze +6% YoY; oncology revenue +10% YoY.
- Zanidatamab granted Priority Review; PDUFA Nov 29, 2024 for 2L BTC.
- Narrowed 2024 total revenue guidance to $4.0-$4.1B; lowered oncology outlook to $1.10-$1.15B.
- GAAP EPS guidance raised to $6.00-$8.00; non-GAAP EPS to $19.20-$20.30.
- GAAP net income affirmed $385-$530M; non-GAAP adjusted net income $1.275-$1.350B.

## SEC filing metadata
- accession: 0001232524-24-000065
- form_type: 8-K
- ticker: JAZZ
- cik: 0001232524
- company_name: Jazz Pharmaceuticals plc
- filed_at: 2024-07-31T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1232524/000123252424000065/0001232524-24-000065-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1232524/000123252424000065/jazz-20240731.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001232524-24-000065
- JSON: https://secwatch.observer/filing/0001232524-24-000065.json
- Plain text: https://secwatch.observer/filing/0001232524-24-000065.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.